THIS IS WHERE THE FUTURE IS FOR GCAN!!!!!
Symtomax are at the forefront to offer cheaper production, providing products at the certification grade Europe requires. With current demand outstripping supply in the European Union, it’s easy to see why Symtomax are confident about how they have positioned themselves. Symtomax’s vision and strategic direction is evident in the recently announced partnership. In May of this year Symtomax and Greater Cannabis Company a publicly traded biopharmaceutical, based out of Baltimore, with a focus on the development and commercialisation of cannabinoid delivery systems, signed a joint agreement giving rights to use their tested patented delivery products & distribution throughout Europe, Middle East and Africa.
With concern growing over vaping and the numerous incidents now being reported, Symtomax’s new oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.
This new Innovative delivery system using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, provides for a needle free, intra-oral systemic drug delivery.
Paul Segal, Chairman said: “Our focus has always been on providing safe, accessible, alternative medicines, with patients and consumers demanding safer routes of administration, while achieving proper potency and higher bioavailability, we believe we can now meet this need as well as the expectations.”
Symtomax have established sales and distribution arrangements to supply their cannabinoid-containing products through major pharmaceutical distribution channels throughout Portugal and the European Union (EU). The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration.
RUN BY THESE PEOPLE!!!!!
With Symtomax looking to invest over €30m over the next five years ensuring that they lead the cultivation process in Europe.
Symtomax is managed by CEO and Founder Minette Coetzee, whose entrepreneurial instincts and vision have rapidly positioned them as a major powerhouse in the cultivation world within the European Union. An impressive team, with the likes of Eurico Carlos Alves a Professor of Surgery at the Integrated Master of Medicine of the Institute of Biomedical Sciences and former State Secretary of Health and Chairman of the Infarmed Board of Directors. David Mace, ex GW pharmaceutical Audit Chairman, and Olaf van Tulder CEO of Green House Group (strain hunters) and over 25 years’ experience in the cultivation of cannabis on a commercial level.
Market Data 
Markets 
AI
